microdosing tirzepatide for inflammation Program Tirzepatide Microdosing: The Growing Off-Label

May 16, 2026- A new study from Veterans Affairs, published last month in JAMA Network Open, adds further weight to a growing body of evidence connecting GLP-1 medications to a heightened risk of non-arteritic anterior ischemic optic neuropathy, or NAION a condition in which damage to the optic nerve can cause symptoms ranging from mild vision disturbances to permanent blindness

Compounded semaglutide is typically supplied as a multi-dose vial with a concentration measured in mg/mL

Im not here to judge that

Drug companies/ for profits do the trials

Further research, including long-term evaluation of sarcopenia in GLP-1RAs trials, development of standardized monitoring protocols and investigation of combined nutritional, exercise and pharmacologic strategies, is needed in order to prevent muscle loss while maximizing metabolic benefits under GLP-1RAs treatment